Business Context and Reporting Period
Company: DENTSPLY SIRONA Inc. (XRAY)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: The world's largest diversified manufacturer of professional dental products and technologies, operating through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company serves approximately 140 countries.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Net Sales | $3,680 million | $3,793 million | (3.0%) |
| Gross Profit | $1,840 million | $1,958 million | (6.0%) |
| Gross Margin | 50.0% | 51.6% | (160 bps) |
| Operating Loss | $(422) million | $(879) million | Improvement |
| Net Loss | $(598) million | $(910) million | Improvement |
| Diluted Loss Per Share | $(3.00) | $(4.48) | Improvement |
| Cash Flow from Operations | $235 million | $461 million | (49.0%) |
| Net Debt | $2,002 million | $1,863 million | 7.5% Increase |
| Total Equity | $1,340 million | $1,943 million | (31.0%) |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 3.0% (4.3% on a constant currency basis). The decline was driven by lower volumes in the Orthodontic and Implant Solutions segment due to the suspension of Byte sales and lower CAD/CAM and implant volumes, particularly in the U.S.
- Impairment Charges: Total goodwill and intangible asset impairments were $650 million, a significant decrease from $1,014 million in 2024. This reduction was the primary driver for the improvement in net loss.
- Segment Performance:
- Connected Technology Solutions: Sales down 2.5% due to lower CAD/CAM volumes.
- Essential Dental Solutions: Sales up 1.1% despite higher customer incentives.
- Orthodontic and Implant Solutions: Sales down 12.6% primarily due to the Byte aligner suspension.
- Wellspect Healthcare: Sales up 6.6% driven by higher volumes and new product launches.
- Working Capital: Cash flow from operations decreased significantly due to higher accounts receivable (timing of sales) and increased inventory builds.
Guidance, Outlook, and Risks
- Restructuring (2026 Plan): In February 2026, the Board approved a new restructuring plan expected to incur $55–$65 million in non-recurring charges (mostly in 2026–2027) with anticipated annualized cost savings of $120 million.
- Dividend Suspension: The Board eliminated the declaration of quarterly dividends starting with the quarter ending March 31, 2026.
- R&D Investment: The company plans to increase R&D investment to approximately 5% of net sales beginning in 2026, up from a historical 4%.
- Key Risks:
- Geopolitical: Ongoing conflicts in Russia-Ukraine and the Middle East impact supply chains and currency repatriation (specifically $56 million cash trapped in Russia).
- Regulatory: Continued exposure to EU MDR certification deadlines and potential impacts from new U.S. tax laws (OBBBA) and global minimum tax (Pillar Two).
- Cybersecurity: Increased reliance on cloud platforms (DS Core) and AI introduces new vulnerabilities.
- Legal: Pending securities class actions regarding revenue recognition and the Byte acquisition; a German tax investigation regarding intercompany loans.
Investor Verification Checklist
- Byte Aligner Exit: Verify the final financial impact of the Byte suspension, including remaining refund liabilities and the full write-off of the trademark.
- Impairment Sustainability: Assess whether the $650 million impairment charge in 2025 represents a one-time correction or if further goodwill impairments are likely given the continued decline in the Implant & Prosthetic Solutions reporting unit.
- Liquidity Position: Review the company's ability to service $2.276 billion in long-term debt maturities and the impact of the dividend suspension on cash preservation.
- ERP Implementation: Monitor the progress and cost overruns of the new global ERP system, which poses risks to financial reporting and operations.
- Legal Contingencies: Track the status of the securities class actions and the German tax investigation for potential material liabilities.